Cardiovascular mortality trends among people with and without diabetes [0.03%]
糖尿病患者和非糖尿病患者的心血管疾病死亡率变化趋势
Ranjit Mohan Anjana
Ranjit Mohan Anjana
Time trends in mortality from heart failure and atherosclerotic cardiovascular disease in people with and without diabetes: a multi-national population-based study [0.03%]
糖尿病患者和非糖尿病患者的心力衰竭和动脉粥样硬化性心血管疾病死亡率的时间趋势：一项跨国人群研究
Joanna Y Gong,Jedidiah I Morton,Lei Chen et al.
Joanna Y Gong et al.
Background: Contemporary trends in cardiovascular disease (CVD) cause-specific mortality by diabetes status are inadequately described. We examined trends by diabetes status in coronary heart disease (CHD), cerebrovascula...
Dual incretin therapy for type 2 diabetes inadequately controlled on basal insulin in Chinese adults: clinical and research implications [0.03%]
中国成人基础胰岛素治疗控制不佳的2型糖尿病患者使用双源肠促胰素治疗的临床和研究意义
Tongzhi Wu,Christopher K Rayner,Karen L Jones et al.
Tongzhi Wu et al.
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial [0.03%]
中国2型糖尿病患者的基础胰岛素添加 tirzepatide 治疗疗效和安全性Ⅲ期临床研究（SURPASS-CN-INS）：一项多中心、随机、双盲、安慰剂对照试验
Lixin Guo,Xiaolin Dong,Jianhua Ma et al.
Lixin Guo et al.
Background: Data on tirzepatide added to basal insulin in patients with type 2 diabetes in China are scarce. We aimed to evaluate the efficacy and safety of tirzepatide added to basal insulin in this population. ...
Maurizio Bifulco,Cristina Pagano,Erika Di Zazzo
Maurizio Bifulco
Raul D Santos,Samuel S Gidding,Mafalda Bourbon et al.
Raul D Santos et al.
Heterozygous familial hypercholesterolaemia is a common, autosomal semi-dominant condition characterised by elevation of LDL cholesterol from birth and early onset of atherosclerotic cardiovascular disease. With major advances in knowledge ...
Laura Downey,Hanne Ballhausen,Louise Hatherall et al.
Laura Downey et al.
Managing adults with screen-detected islet autoantibody positivity: a pragmatic framework [0.03%]
筛查发现胰岛自身抗体阳性成人管理的务实框架
Nicholas Thomas,Danijela Tatovic,Angus Jones et al.
Nicholas Thomas et al.
New disease-modifying therapies, such as teplizumab, offer opportunities to delay the clinical onset of type 1 diabetes but require islet autoantibody screening to identify individuals at increased risk of progression to diabetes. As type 1...